Surgical site infections (SSIs) are a common and serious complication following appendectomy, yet practical tools for individualized risk stratification are lacking. In resource-limited settings, wher
Galunisertib (LY2157299), a selective ATP-mimetic inhibitor of TGF-β receptor I (TGF-βRI), is the only known TGF-β pathway inhibitor. In the present study, we investigated the effect of galunisertib o